EUVIMEDEUVIMED entdecken
Crossref

PTK7 helps detect T lymphoblastic leukemia/lymphoma by flow cytometry

Jonah Maggard, Yu Yang, Joanna Chaffin, Eric Gars, Lijun Yang, Robert Seifert iD

Cytometry Part B: Clinical Cytometry · 2025

DOI: 10.1002/cyto.b.22228 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cytometry Part B: Clinical Cytometry, 2025. Verfasst von Jonah Maggard und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of Florida College of Medicine, Gainesville, Florida, USA. Hauptthemen laut MEDLINE: Flow Cytometry, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Receptor Protein-Tyrosine Kinases, Cell Adhesion Molecules. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T lymphoblastic leukemia/lymphoma (T‐ALL) is a malignancy composed of proliferating T lymphoblasts. T lymphoblasts can be identified by flow cytometric analysis through the detection of aberrant antigen expression and/or immaturity marker expression. An ideal marker would be expressed brightly on T lymphoblasts but absent in mature T lymphocytes. One such marker is protein tyrosine kinase‐7 (PTK7). However, PTK7 has not been widely adopted in clinical flow cytometry labs or incorporated into any T‐ALL flow cytometry best practice recommendations. To this end, we demonstrate the utility of PTK7 in flow cytometry panels for T‐ALL diagnosis, minimal/measurable residual disease (MRD) detection, and relapse. We retrospectively evaluated flow cytometry data on 175 patients. PTK7 was classified as positive, showing a near two‐fold difference in brightness versus background mature T cells, in 87.76% of T‐ALL cases at initial diagnosis, 75% of T‐ALL at MRD, and 100% of T‐ALL at relapse. PTK7 expression remained intact in cases of CD34 and/or TdT negative T‐ALL ( p = 0.992) and while expression was dimmer at MRD (72% decrease, p = 0.0313), PTK7 remained intact at relapse (33% increase, p = 0.8125). PTK7 should be included in flow cytometry panels when evaluating for T‐ALL, both at initial diagnosis, relapse, and for the presence of MRD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Flow CytometryPrecursor T-Cell Lymphoblastic Leukemia-LymphomaReceptor Protein-Tyrosine KinasesCell Adhesion MoleculesBiomarkers, TumorHumansFemaleMaleAdultRetrospective StudiesChildNeoplasm, ResidualAdolescentMiddle AgedChild, PreschoolYoung AdultT-Lymphocytes

Stichwörter der Autor:innen

MRDPTK7T‐ALLT‐LBLflow cytometry

Substanzen

PTK7 protein, humanReceptor Protein-Tyrosine KinasesCell Adhesion MoleculesBiomarkers, Tumor

Autor:innen und Institutionen

  • University of Florida College of Medicine, Gainesville, Florida, USA.
  • Department of Pathology, Immunology and Laboratory Medicine, Gainesville, Florida, USA.

ORCID-Profile: Robert Seifert

Zitieren

APA

Maggard, J., Yang, Y., Chaffin, J., Gars, E., Yang, L., & Seifert, R. (2025). PTK7 helps detect T lymphoblastic leukemia/lymphoma by flow cytometry. Cytometry Part B: Clinical Cytometry. https://doi.org/10.1002/cyto.b.22228

Vancouver

Maggard J, Yang Y, Chaffin J, Gars E, Yang L, Seifert R. PTK7 helps detect T lymphoblastic leukemia/lymphoma by flow cytometry. Cytometry Part B: Clinical Cytometry. 2025. doi:10.1002/cyto.b.22228

BibTeX
@article{Maggard2025,
  author = {Maggard, Jonah and Yang, Yu and Chaffin, Joanna and Gars, Eric and Yang, Lijun and Seifert, Robert},
  title = {PTK7 helps detect T lymphoblastic leukemia/lymphoma by flow cytometry},
  journal = {Cytometry Part B: Clinical Cytometry},
  year = {2025},
  doi = {10.1002/cyto.b.22228}
}
Kostenlos starten →